Glargine and Glimepiride Combined with Appropriate Exercise Improves Lower Extremity Function and the Blood Glucose Level in Patients with Diabetic Lower Extremity Arterial Occlusive Disease

Abstract

Objective: To analyze the impact of glargine and glimepiride combined with appropriate exercise on improving lower extremity function and blood glucose level in patients with lower extremity arterial occlusive disease (LEAOD). Methods: One hundred thirty patients with diabetic LEAOD were randomly divided on a 1:1 basis (n = 65) in control and research groups according to a random number table. The research group was prescribed glargine and glimepiride combined with appropriate exercise. Results: There were no statistically significant differences in fasting plasma glucose (FPG), 2h postprandial blood glucose (2h PG), glycosylated hemoglobin (HbA1c), insulin function index (HOMA-islet), and insulin resistance index (HOMA-IR) pre-treatment between groups. FPG, 2h PG, HbA1c, HOMA-islet, and HOMA-IR levels were significantly lower in the research group than in the control group post-treatment. Moreover, the rate of improvement was greater in the research group than the control group. The incidence of adverse events during treatment was lower in the research group than in the control group. Conclusions: Glargine and glimepiride combined with appropriate exercise in patients with diabetic LEAOD effectively controlled blood glucose level, improved insulin activity, and promoted recovery of lower extremity function.